Vaxart Files 8-K for Undisclosed Event on Feb 14, 2024
Ticker: VXRT · Form: 8-K · Filed: Feb 15, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K Filing, Corporate Update, Regulatory Filing
TL;DR
**Vaxart filed an 8-K on Feb 15 for an unspecified event from Feb 14; details are pending.**
AI Summary
Vaxart, Inc. filed an 8-K Current Report with the SEC on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates "Other Events" and "Financial Statements and Exhibits" were reported, but the provided text does not detail the specific nature of these events or exhibits. Vaxart, Inc. has a CIK of 0000072444 and is based in South San Francisco, CA.
Why It Matters
This filing signals that Vaxart, Inc. has reported a corporate event to the SEC, which could potentially impact its operations or financial standing. Without the full content, the specific real-world implications remain unknown to investors.
Risk Assessment
Risk Level: low — The provided text is only metadata for an 8-K filing, not the content of the event itself, thus no specific risks are identifiable from this snippet.
Key Players & Entities
- Vaxart, Inc. (company) — registrant
- 03 Life Sciences (company) — organization name related to filer
- Aviragen Therapeutics, Inc. (company) — former company name of Vaxart, Inc.
- Biota Pharmaceuticals, Inc. (company) — former company name of Vaxart, Inc.
- NABI BIOPHARMACEUTICALS (company) — former company name of Vaxart, Inc.
FAQ
What type of SEC filing is this document?
This document is an 8-K, a Current Report, filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the name of the registrant company?
The registrant company is Vaxart, Inc.
When was the earliest event reported in this filing?
The earliest event reported was on February 14, 2024.
What is Vaxart, Inc.'s Central Index Key (CIK) number?
Vaxart, Inc.'s Central Index Key (CIK) is 0000072444.
What items are mentioned in the ITEM INFORMATION section of this 8-K?
The ITEM INFORMATION section mentions "Other Events" and "Financial Statements and Exhibits."
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-02-15 16:10:21
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
- $1.00 — ock had a closing bid price of at least $1.00 per share for ten consecutive business
Filing Documents
- vxrt20240215_8k.htm (8-K) — 27KB
- 0001437749-24-004353.txt ( ) — 155KB
- vxrt-20240214.xsd (EX-101.SCH) — 3KB
- vxrt-20240214_def.xml (EX-101.DEF) — 11KB
- vxrt-20240214_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240214_pre.xml (EX-101.PRE) — 11KB
- vxrt20240215_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On February 14, 2024, Vaxart, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company had regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) because the Company's common stock had a closing bid price of at least $1.00 per share for ten consecutive business days.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaxart, Inc. Dated: February 15, 2024 By: /s/ MICHAEL J. FINNEY Michael J. Finney, Ph.D. Interim Chief Executive Officer